| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.4 |